2-苯基吡咯烷 | 1006-64-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-苯基吡咯烷
• 中文别名: 2-苯基吡咯啉；2-苯基吡咯
• 英文名称: 2-(phenyl)pyrrolidine
• 英文别名: (±)-2-phenylpyrrolidine；NSC 94961；2-Phenylpyrrolidine
• CAS: 1006-64-0
• 化学式: C₁₀H₁₃N
• mdl: MFCD01631835
• 分子量: 147.22
• InChiKey: JUTDHSGANMHVIC-UHFFFAOYSA-N

物化性质

• 熔点：
  42-43 °C
• 沸点：
  68°C
• 密度：
  0.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36/37/39
• 海关编码：
  2933990090
• 危险品标志：
  Xn,Xi
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放于惰性气体中，避免与空气接触。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Phenylpyrrolidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
H412: Harmful to aquatic life with long lasting effects
P273: Avoid release to the environment
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Phenylpyrrolidine
CAS number: 1006-64-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H13N
Molecular weight: 147.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯基吡咯烷 在 2-碘吡啶 、 三氟甲磺酸酐 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 16.25h， 生成 6-(4-methylthiophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline-5-one
  参考文献：
  名称：

  olo物种的原位产生的无金属形式的氧化C-C偶联

  摘要：

  当代许多有机合成都依赖于化学键和反应中心固有的，所谓的“天然”极性驱动的转变。非常规极化合成子的设计是非常需要的策略，因为它通常能够实现复杂物质合成的空前的逆合成断开。羰基中心的空位化是众所周知的策略，而羰基α位的极性反转要少得多。在本文中，我们报告了一种新型亲电子en烯的设计及其在高效和化学选择性，无金属的氧化C-C偶联中的应用。

  DOI：

  10.1002/anie.201701538
• 作为产物：
  描述：

  2-苯基-1-(4-甲基苯磺酰)吡咯烷 在 magnesium 作用下， 以 甲醇 为溶剂， 以85%的产率得到2-苯基吡咯烷
  参考文献：
  名称：

  钙（II）催化六氟异丙醇中未活化烯烃的分子内和分子间加氢酰胺化

  摘要：

  发现三氟化钙（II）盐和六氟异丙醇（HFIP）的组合是用于未活化烯烃的分子内和分子间加氢酰胺化的高效促进剂体系。与其他方法不同，在氮和烯烃部分可以容忍大量官能团。该反应以优异的产率和良好的非对映选择性产生了相应的含氮化合物。事实证明，使用HFIP作为溶剂对于正确进行此转化至关重要。通过DFT计算合理化了它的作用，以及钙及其NTf 2配体的作用。这些计算表明[（NTf 2）Ca（HFIP）n ] +配合物如何通过NTf的碱性位点活化酰胺。2个配体和烯烃带有一个酸性HFIP质子。与钙中心的配位会加剧HFIP的酸度，随着n的增加而增加。

  DOI：

  10.1021/acscatal.7b04271
• 作为试剂：
  描述：

  对硝基苯甲醛 、 丙酮 在 2-苯基吡咯烷 、 phosphate buffer 作用下， 以 水 、 二甲基亚砜 为溶剂， 生成 1-(4-硝基苯基)-3-氧代-1-丁醇
  参考文献：
  名称：

  Hammett Correlation of Nornicotine Analogues in the Aqueous Aldol Reaction:  Implications for Green Organocatalysis

  摘要：

  A series of meta- and para-substituted 2-arylpyrrolidines were synthesized and examined for their ability to catalyze an aqueous aldol reaction under buffered conditions. Kinetic analysis of arylpyrrolidine-catalyzed reactions displayed a linear Hammett correlation with rho = 1.14 (R-2 = 0.996), indicating that the reaction is accelerated by electron-withdrawing aryl rings. These results show promise for the development of a synthetically viable aqueous organo-catalyst.

  DOI：

  10.1021/jo050161r

文献信息

• 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080214520A1

  公开（公告）日：2008-09-04

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R 6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

  本发明提供了Formula I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：Formula (I)其中：R6选自(a、b、c、d、e)等基团组成的群，其他取代基如规范中定义。
• Palladium-catalyzed ortho-olefination of 2-arylpyrrolidines: A tool for increasing structural complexity in nitrogen heterocycles
  作者：Pablo D. Legarda、Alfonso García-Rubia、Ramón Gómez Arrayás、Juan C. Carretero

  DOI：10.1016/j.tet.2018.05.076

  日期：2018.7

  of the (2-pyridyl)sulfonyl unit as directing functionality and readily removable N-protecting group has enabled an efficient and practical transformation of 2-arylpyrrolidine derivatives into more complex tricyclic frameworks via palladium-catalyzed ortho-olefination with electron deficient alkenes and subsequent cyclization upon N-deprotection under mild conditions. The key cross coupling step in the

  （2-吡啶基）磺酰基单元作为直接官能团和易于除去的N-保护基团的双重作用使得能够通过钯催化的与缺电子烯烃的邻位烯烃化反应将2-芳基吡咯烷衍生物有效而实用地转化为更复杂的三环骨架。和随后在温和条件下在N-脱保护下环化。在三氟甲磺酸N-氟-2,4,6-三甲基吡啶鎓（[F +]）的存在下，关键的交叉偶联步骤既高效又可耐受两个偶联伙伴处的各种空间和电子变化。通过的还原条件适当选择，Ñ-磺酰基脱保护基可以选择性地形成苯并-稠合的吡咯烷或稠合的吡咯烷基-苯并氮杂framework骨架。
• Synthesis of 3-Aryl-1-aminopropane Derivatives: Lithiation–Boryl­ation–Ring-Opening of Azetidinium Ions
  作者：Giorgia Casoni、Eddie Myers、Varinder Aggarwal

  DOI：10.1055/s-0035-1562447

  日期：2016.10

  C–B bond of the γ-dimethylamino tertiary boronic esters can be transformed into a variety of functional groups (C–OH, C–vinyl, C–H, C–BF3), thus giving a diverse selection of 3-aryl-1-aminopropanes, which represent a privileged motif among drug molecules. In situ generated 2-phenyl-azetidinium ylides react with boronic esters to form acyclic γ-dimethylamino tertiary boronic esters. The transformation

  致力于纪念Jean Normant教授 抽象的 原位生成的2-苯基-氮杂环丁烷基鎓盐与硼酸酯反应形成无环的γ-二甲基氨基叔硼酸酯。据信该转化涉及两性离子硼酸酯的形成，其随后经历开环的1，2-迁移，其通过消除环应变而促进。由于最初形成的伊利德的构型不稳定性似乎与开链卡宾形式处于平衡状态，因此该反应不是立体特异性的。γ-二甲基氨基叔硼酸酯的C–B键可以转化为各种官能团（C–OH，C–乙烯基，CH–H，C–BF 3），从而提供了多种多样的3-芳基选择-1-氨基丙烷代表药物分子中的优先基序。 原位生成的2-苯基-氮杂环丁烷基鎓盐与硼酸酯反应形成无环的γ-二甲基氨基叔硼酸酯。据信该转化涉及两性离子硼酸酯的形成，其随后经历开环的1，2-迁移，其通过消除环应变而促进。由于最初形成的伊利德的构型不稳定性似乎与开链卡宾形式处于平衡状态，因此该反应不是立体特异性的。γ-二甲基氨基叔硼酸酯的C–B键可以转化为各
• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• CHEMICAL COMPOUNDS
  申请人：Deng Jianghe

  公开号：US20090143372A1

  公开（公告）日：2009-06-04

  The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型吲哚羧酰胺衍生物。具体而言，该发明涉及符合以下式I的化合物： 其中R1、R2、R3、U和V如下定义，并且其药学上可接受的盐。该发明的化合物是IKK2的抑制剂，可用于治疗与不当IKK2（也称为IKKβ）活性相关的疾病，如类风湿性关节炎、哮喘和慢性阻塞性肺病（COPD）。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制IKK2活性和治疗相关疾病的方法。